BGC > Produktsuche > LY2562175 | 1103500-20-4

Description:
LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. It was developed by Eli Lilly and Company and in clinic phase 1 trials with no progress.

• Molecular Weight:540.44
• Boiling Point:740.1±60.0 °C | Condition: Press: 760 Torr
• Purity:>98%

Molecular Formula:
C28H27Cl2N3O4
Canonical SMILES:
CN1C=C(C2=C1C=C(C=C2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C(=O)O
InChI:
InChI=1S/C28H27Cl2N3O4/c1-32-14-20(28(34)35)19-8-7-17(13-24(19)32)33-11-9-18(10-12-33)36-15-21-26(31-37-27(21)16-5-6-16)25-22(29)3-2-4-23(25)30/h2-4,7-8,13-14,16,18H,5-6,9-12,15H2,1H3,(H,34,35)
InChIKey:
RPVDFHPBGBMWID-UHFFFAOYSA-N
Solubility:
10 mM in DMSO
Appearance:
Solid powder
Application:
LY2562175 has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species.
Storage: -20°C Freezer
Synonyms:
LY2562175; LY 2562175; LY-2562175;6-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid